Comparison of the Pharmacokinetic Profiles of Ceftriaxone Used Alone and Combined with Danhong Injection in Old Rats
- 13 Downloads
Background and Objectives
Danhong injection is the most commonly prescribed adjuvant drug applied for the treatment of cardiovascular and cerebrovascular diseases in China. Ceftriaxone is usually prescribed along with Danhong injection to elderly patients with complications. However, the pharmacokinetic interactions between these two medications have not been investigated. The aim of this study was to investigate whether Danhong injection influences the pharmacokinetic profile of ceftriaxone in old rats when these two medications are used in combination.
The animal experiment protocol was designed according to the clinical data. Ten-month-old male Sprague–Dawley (SD) rats were dosed with ceftriaxone through intravenous administration for 1 or 7 days in the presence or absence of Danhong injection. The combinations were divided into 1-day, 7-day, and 14-day combined-treatment groups in which Danhong injection was administered for 1, 7, or 14 days and ceftriaxone was given for 1, 7, or 7 days, respectively. The plasma concentration of ceftriaxone was determined by ultrahigh performance liquid chromatography coupled with triple-quadrupole mass spectrometry (UHPLC–TQ–MS) on a BEH C18 column with a mobile phase consisting of acetonitrile and 0.4% formic acid–water. The chromatographic method was validated and found to be simple, rapid, and stable.
Danhong injection significantly increased the plasma clearance of and decreased systemic exposure to ceftriaxone. In the 1-day combined-treatment group, the plasma clearance of ceftriaxone increased by 52.69%, and the area under the concentration–time curve (AUC) of ceftriaxone was decreased by 32.54% (P < 0.01). In the 7-day combined-treatment group, the rate of plasma clearance increased by 52.49% and the area under the concentration–time curve decreased by 31.15% (P < 0.01). For the 14-day combined-treatment group, the plasma clearance of ceftriaxone increased by 26.73%, and the area under the concentration–time curve decreased by 21.44% (P < 0.05).
In old male rats, systemic exposure to ceftriaxone decreased when used concomitantly with Danhong injection, which may be because Danhong injection increased the plasma clearance of ceftriaxone. Further investigations should be carried out to clarify the mechanism for the influence of Danhong injection on the pharmacokinetics of ceftriaxone.
We would like to thank Dr. Xiaoxiao Wang for assistance with the data mining of the statistics on the concomitant use of medications with Danhong injection. We gratefully acknowledge Prof. J. A. Duan and Prof. W. Z. Ju for their supervision. We also thank Prof. Z. S. Tang and Prof. B. C. Zhao for their technical and financial support.
Compliance with Ethical Standards
This work was financially supported by the National Basic Research Program of China (973 Program; 2011CB505300, 2011CB505303), the National Technology Major Project of China (2015ZX09501004001006), the Key Research Project in Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization (ZDXM-2-2), the Science and Technology project of the Administration of Traditional Chinese Medicine of Jiangsu Province (YB2017018), and the Research Project and Innovation Program of graduate students at Jiangsu College and University (201510315064Y).
Conflict of interest
Q. Zhang, G. L. Dai, and W. Z. Ju were employees of the Affiliated Hospital of Nanjing University of Chinese Medicine, J. M. Guo, J. P. Li, and J. A. Duan were employees of Nanjing University of Chinese Medicine, and L. J. Zhu, S. F. He, and Y. Zong were employees of the Affiliated Hospital of Nanjing University of Chinese Medicine during the research reported in this paper. All of the authors declare that they have no potential conflict of interest.
All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. All procedures performed in studies involving animals were approved by animal care and use committees where the studies were conducted. This article does not contain any studies with human participants performed by any of the authors.
- 8.Zhang Q, Ju WZ, Guo JM, Li JP, Tan XY, Wang XX, et al. Rationality analysis of the clinical application of Danhong injection in Jiangsu Province hospital of TCM from 2013 to 2014. Zhongguo Zhong Yao Za Zhi. 2016;41(4):748–54.Google Scholar
- 9.Li GH, Jiang HY, Xie YM, Jiang JJ, Yang W, Zhao W, et al. Analysis of traditional Chinese medicine syndrome, traditional Chinese medicine and Western medicine in 84 697 patients with coronary heart disease based on big data. Zhongguo Zhong Yao Za Zhi. 2014;39(18):3462–8.Google Scholar
- 14.Xie YY, Xiao X, Luo JM, Fu C, Wang QW, Wang YM, et al. Integrating qualitative and quantitative characterization of traditional Chinese medicine injection by high-performance liquid chromatography with diode array detection and tandem mass spectrometry. J Sep Sci. 2014;37(12):1438–47. https://doi.org/10.1002/jssc.201400129.CrossRefPubMedGoogle Scholar
- 15.Wang Y, Shao Q, Qu HB, Liu YF. Multiple fingerprints and multi-comonent quantitative analysis of Danhong injection. Zhong Cao Yao. 2014;45(4):490–7.Google Scholar
- 16.Zhang Q, Dai GL, Guo JM, Tan XY, Zhang DS, He SF, et al. Comparison of the quantity of the common components in Danhong injection, Danshen injection and Honghua injection. Chin Hosp Pharm J. 2017;37(15):1435–9.Google Scholar
- 20.Wang L, Venitz J, Sweet DH. Cumulative organic anion transporter-mediated drug–drug interaction potential of multiple components in Salvia miltiorrhiza (Danshen) preparations. Pharm Res. 2014;31(12):3503–14. https://doi.org/10.1007/s11095-014-1437-9.
- 21.Patel IH, Chen S, Parsonnet M, Hackman MR, Brooks MA, Konikoff J, et al. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother. 1981;20(5):634–41.Google Scholar
- 23.Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, et al. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos. 2008;36(6):1088–96. https://doi.org/10.1124/dmd.107.019125.CrossRefPubMedGoogle Scholar
- 26.Nakaharai K, Sakamoto Y, Yaita K, Yoshimura Y, Igarashi S, Tachikawa N. Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score. Eur J Clin Pharmacol. 2016;72(8):1003–11. https://doi.org/10.1007/s00228-016-2064-7.CrossRefPubMedGoogle Scholar
- 28.Zhang Q, Ju WZ, Guo JM, Li JP, Wang XX, Dai GL, et al. A literature review on the drug–drug interactions between Danhong injection and its common combination based on clinical statistics. Chin Hosp Pharm J. 2016;36(9):43–7.Google Scholar
- 31.Yu J, Yang LH, Hu CQ, Yan ZY. Degradation test of ceftriaxone sodium and structure identification of its degradation products. Central South Pharm. 2014;12(2):106–9. https://doi.org/10.7539/j.issn.1672-2981.2014.02.003.CrossRefGoogle Scholar
- 37.Brown GR. Cephalosporin–probenecid drug interactions. Clin Pharmacokinet. 1993;24(4):289–300.Google Scholar
- 38.Zhang Q, Dai GL, Ju WZ, Guo JM, Sun BT, Zong Y, et al. Determination of biding rates of human plasma protein with seven bioactive components in Danhong injection. Chin Pharmacol Bull. 2017;33(5):712–8.Google Scholar
- 39.Owoicho Orgah J, Wang M, Yang X, Wang Z, Wang D, Zhang Q, et al. Danhong injection protects against hypertension-induced renal injury via down-regulation of myoglobin expression in spontaneously hypertensive rats. Kidney Blood Press Res. 2018;43(1):12–24. https://doi.org/10.1159/000486735.CrossRefPubMedGoogle Scholar